 |
 |
IDEAL International Conference 2017
Research, Regulation, and Reimbursement in Surgery and Technologies
When and where: May 4th-5th 2017, New York Academy of Medicine,
New York City
Twitter @IDEALCollab
Promoting innovation and evaluation in modern surgery and other invasive technologies including implants is one of the main challenges in healthcare. IDEAL is a development of Evidence Based Medicine approach designed to provide practical solutions to the real problems of surgery, devices and other complex therapies where randomised trials are often problematic. The second IDEAL international conference will focus on the hottest topics in surgical/interventional care in various clinical areas and celebrate the continuing work of the IDEAL Collaboration. The conference will provide real-world context and a wide variety of perspectives including surgeons, methodologists, professional societies, industry, regulators, ethicists, and payers. Plenary lectures will be intermixed with parallel educational sessions and opportunities for surgeons and scientists to discuss hot topics in surgery, devices and present their own innovative work.
Registration is now open at www.ideal-conference2017.com – early registration discount available until February 28th! Registration fees include breakfast and lunch each day of the conference, and CME credits will be available for physicians. For further information, contact: [log in to unmask] or visit www.ideal-collaboration.net.
Abstract submission is now open! CLICK HERE to access the submission system and to view the full list of abstract categories. The submission deadline is Saturday, March 11th, 2017. Abstracts will be accepted in a wide variety of clinical areas, including but not limited to urology, orthopaedics, vascular surgery, abdominal surgery, and cardiothoracic surgery.
Official invitations can be provided on request to international attendees who may require documentation to obtain a travel visa. Please assist the IDEAL community by disseminating the meeting flyer to colleagues!
IDEAL Background Readings:
§ Evaluation and stages of surgical innovations. Barkun et al, 2009. Lancet.
§ No surgical innovation without evaluation: the IDEAL recommendations. MuCulloch et al, 2009. Lancet.
§ IDEAL-D: a rational framework for evaluating and regulating the use of medical devices. Sedrakyan et al, 2016. BMJ.
§ Challenges in evaluating surgical innovation. Ergina et al, 2009. Lancet.
§ IDEAL framework for surgical innovation 1: the idea and development stages. McCulloch et al, 2013. BMJ.
§ IDEAL framework for surgical innovation 2: observational studies in the exploration and assessment stages. Ergina et al, 2013. BMJ.
§ IDEAL framework for surgical innovation 3: randomised controlled trials in the assessment stage and evaluations in the long term study stage. Cook et al, 2013. BMJ.
§ Practical guide to the Idea, Development and Exploration stages of the IDEAL Framework and Recommendations. Pennell et al, 2016. Br J Surg.
Early Confirmed Speakers (February 8, 2017):
§ Murray Sheldon, MD, Associate Director for Technology and Innovation, FDA
§ Vipul Patel, MD, Medical Director, Global Robotics Institute, Celebration, FL
§ Binita Ashar, MD, Director, Division of Surgical Device, Office of Device Evaluation, FDA
§ Joel Horovitz, MD, Vice Chair of Surgery, Maimonides Medical Center
§ Andrew Carr, MD, Head of Rheumatology and Musculoskeletal Sciences, University of Oxford
§ Danica Marinac-Dabic, MD, PhD, Director, Division of Epidemiology, FDA
§ Jesse Berlin, ScD, Vice President and Global Head, Epidemiology, Johnson & Johnson
§ Art Sedrakyan, MD, PhD, Professor of Healthcare Policy and Research, Weill Cornell Medicine
§ Ajit Sachdeva, MD, Director, Division of Education, American College of Surgeons
§ Peter McCulloch, MD, Professor of Surgical Science and Practice, University of Oxford
§ Philipp Dahm, MD, Professor of Urology, University of Michigan
§ Bruce Campbell, MD, Director Medicines & Healthcare Products Registry Agency (MHRA, UK)
§ Tammy Clifford, PhD, Vice-President, Medical Device & Rapid Response Programs, CADTH, CA
§ Mitchell Roslin, MD, Professor, Hofstra Northwell School of Medicine
§ Kazuhiro Sase, MD, PhD, Professor, Juntendo University and PMDA, Japan
§ Martin Björck, MD, Professor of Vascular Surgery, Uppsala University Hospital, Sweden
§ Philip Goodney, MD, Associate Professor of Surgery, The Dartmouth Institute
§ Sean Tunis, MD, President and CEO, Center for Medical Technology Policy, Baltimore, MD
§ Jim Hu, MD, Ronald Lynch Professor of Urologic Oncology, Weill Cornell Medicine
§ Jeffrey Milsom, MD, Chief of Colon and Rectal Surgery, NewYork-Presbyterian
§ Jeffrey Levy, MD, Founder and CEO, Case Network
§ Martin Martino, MD, Medical Director, Minimally Invasive Robotic Surgery, Lehigh Valley
§ William Murray, President and CEO, Medical Device Innovation Consortium
§ Dawn Bardot, PhD, Vice President, Technology Innovation, MDIC
§ David Beard, MD, Professor of Musculoskeletal Sciences, University of Oxford
§ Roberto Bergamaschi, MD, PhD, Professor of Surgery, Stony Brook School of Medicine
§ Theodore Lystig, PhD, Director, Corporate Biostatistics, Medtronic
§ Jose Merino, MD, US Clinical Research Editor, BMJ
§ Stephen Graves, MD, Director, Australian National Joint Replacement Registry
§ Jane Blazeby, MD, Professor of Surgery, University of Bristol
§ Cynthia Long, MD, Medical Officer, Division of Reproductive, Gastro-Renal, and Urological Devices, FDA
§ Fred Weaver, MD, Professor of Clinical Surgery, University of Southern California
§ Jonathan Boyle, MD, General Surgery (Vascular), Cambridge University Hospitals
